6-溴苯并二氢吡喃 | 3875-78-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡喃类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 6-溴苯并二氢吡喃
• 中文别名: 6-溴色满；6-溴苯并吡喃
• 英文名称: 6-bromochromane
• 英文别名: 6-bromo-chroman；6-Bromochroman；6-bromo-3,4-dihydro-2H-chromene
• CAS: 3875-78-3
• 化学式: C₉H₉BrO
• 分子量: 213.074
• InChiKey: KPFDABVKWKOIME-UHFFFAOYSA-N

物化性质

• 沸点：
  143-144 °C(Press: 18 Torr)
• 密度：
  1.465 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  6-溴苯并二氢吡喃 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 四(三苯基膦)钯 potassium phosphate 、 potassium acetate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 methyl 2-(chroman-6-yl)-3-(isopropyl(methyl)amino)quinoxaline-6-carboxylate
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  [FR] COMPOSÉS HÉTÉROCYCLIQUES POUR L'INHIBITION DE LA KINASE DE DOMAINE PAS (PASK)

  摘要：

  公开号：

  WO2012119046A3
• 作为产物：
  描述：

  6-溴苯并二氢吡喃-2-酮 在 三乙基硅烷 、 Amberlyst 15 、 polymethylhydrosiloxane 、 (η(5)-C5H5)2Ti(OC6H4Me-p)2 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 6-溴苯并二氢吡喃
  参考文献：
  名称：

  Convenient Two-Step Conversion of Lactones into Cyclic Ethers

  摘要：

  DOI：

  10.1021/jo9716082

文献信息

• Synthesis and Antifungal Activity of Some Thiazole Derivatives
  作者：Ya-Li Song、Xiao-Ming Liu、Ning Yang、Geng-Liang Yang

  DOI：10.14233/ajchem.2013.13185

  日期：——

  A series of some thiazole derivatives were designed and synthesized. The structure of newly synthesized compounds was characterized by HRMS, 1H NMR and 13C NMR. The synthesized compounds were evaluated against ten species of fungi in vitro by agar cup plate and micro-titration methods, respectively. The results of antifungal screening reveal that among all the compounds screened three compounds showed moderate antifungal activity. The MIC value of 3 h against two fungal strains C. neoformans and C. albicas is 8 μg mL-1 respectively. The MIC value of 3i against two fungal strains C. neoformans and T. mentagrophytes is 8 μg mL-1 and 16 μg mL-1, respectively and 3a against T. mentagrophytes is 16 μg mL-1, the MIC of others are all beyond 32 μg mL-1.

  一系列噻唑衍生物的设计与合成得以实现。新型合成化合物的结构通过高分辨质谱（HRMS）、核磁共振氢谱（1H NMR）和碳谱（13C NMR）进行了表征。合成的化合物分别通过琼脂杯平板法和小体积滴定法在体外对十种真菌进行了评估。抗真菌筛选结果显示，在所有筛选的化合物中，有三项展现出中等抗真菌活性。化合物3h对抗两种真菌株C. neoformans和C. albicas的最小抑制浓度（MIC）值分别为8 μg mL-1。化合物3i对抗C. neoformans和T. mentagrophytes的MIC值分别为8 μg mL-1和16 μg mL-1，而3a对抗T. mentagrophytes的MIC值为16 μg mL-1，其余化合物的MIC值均超过32 μg mL-1。
• 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030191181A1

  公开（公告）日：2003-10-09

  Compounds of Formula 1 1 wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  公式1的化合物 1 其中，变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，适用于治疗可用视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030207937A1

  公开（公告）日：2003-11-06

  Compounds of the formula 1 where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  具有公式1的化合物，其中变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并且适用于治疗可通过视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
  申请人：——

  公开号：US20040077721A1

  公开（公告）日：2004-04-22

  vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.

  维生素A，或具有维生素A活性的维生素A衍生物与CP450RAI1和/或CP450RAI2酶的抑制剂共同给药，用于治疗哺乳动物，包括人类的疾病和状况，这些疾病或状况可以通过施用视黄酸化合物或通过哺乳动物机体自然存在的视黄酸来预防、治疗、改善或延迟其发作。
• [EN] INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES<br/>[FR] INHIBITEURS DE RÉPLICATION VIRALE, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：BIODIM LAB

  公开号：WO2012140243A1

  公开（公告）日：2012-10-18

  The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

  本发明涉及化合物，及其在治疗或预防病毒性疾病，包括HIV方面的应用。